Engineering of pan-neutralizing anti-HIV envelope antibodies
全中和抗 HIV 包膜抗体的工程
基本信息
- 批准号:10524019
- 负责人:
- 金额:$ 40.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-12-05 至 2024-11-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS preventionAdherenceAnimal ModelAnti-Retroviral AgentsAntibodiesAntibody Binding SitesAntiviral AgentsAutologousBehaviorBindingBinding SitesBiochemicalCellsCollectionCrystallographyDataDevelopmentDrug CombinationsDrug KineticsEngineeringEnsureExhibitsFaceFamilyGoalsHIVHIV Envelope Protein gp120HIV InfectionsHIV envelope proteinHIV-1HIV/AIDSHalf-LifeHumanIgG1ImmuneIn VitroInfectionLibrariesLife ExtensionLogisticsMediatingMembrane ProteinsMethodsModalityMolecular Sieve ChromatographyMonoclonal AntibodiesMutagenesisNeutralization TestsPassive ImmunizationPassive ImmunotherapyPersonsPharmaceutical PreparationsPlasmaPolysaccharidesPreventionPreventivePropertyRecombinantsResistanceRiskSolubilityStructureSurfaceTarget PopulationsTechniquesTestingVaccinesVariantVirusWorkX-Ray CrystallographyYeastsantibody engineeringbiophysical propertiesclinically relevantcombinatorialdesignexperimental studyhuman monoclonal antibodieshumanized mouseimmunogenicimmunotherapy trialsimprovedin vivointerestmouse modelneutralizing antibodynovelpre-exposure prophylaxisprediction algorithmpreventprophylacticprotective efficacyrecruitside effect
项目摘要
1 Background/Rationale: An alternative pre-exposure prophylaxis modality of growing interest is based on the
2 premise that prevention can be safely achieved by passive immunization with broadly neutralizing anti-HIV
3 antibodies (bNAbs) against the HIV envelope. A pan-neutralizing antibody could provide a feasible means to
4 prevent HIV infection worldwide.
5 Objectives: Our hypothesis is that by rational engineering of near pan-neutralizing bNAbs against the CD4
6 binding site (CD4bs) bNAbs N49P7 and N49P9.3, using rare resistance variants of HIV as guides, a pan-
7 neutralizing with clinically relevant pharmacokinetic profiles can be made. Such a pan-neutralizing antibody
8 would even cover variants that are cross-resistant to other anti-CD4bs bNAbs (3BNC117 and N6). We have
9 preliminary data demonstrating that N49P7 and N49P9.3 are near pan-neutralizing and exhibit novel structural
10 features (e.g., N49P7 has access to the highly conserved inner domain) that can be used to guide improved
11 bNAb design. These unique features provide the closest possible starting point for building a highly potent pan-
12 neutralizing antibody. In parallel, our collaborators have developed techniques to engineer bNAbs, increasing
13 the potency of PGT121 approximately 50 times, while retaining favorable qualities (solubility and non-
14 auto/polyreactivity). The specific aims of this proposal are 1) Engineer N49P7 and N49P9.3 to improve
15 neutralization of HIV-1 viruses resistant to CD4bs bNAbs; 2) Downselection of bNAb variants from Aim 1
16 based on in vivo pharmacokinetics and biophysical properties; 3) Test engineered N49 bNAbs in two
17 humanized mouse models using resistant viruses to determine their efficacy in preventing HIV-1 infection.
18 Methods: Our plan is to make a collection of N49P7 and N49P9.3 variants with greater potency and breadth
19 using yeast surface display, focusing on selecting variants with enhanced recognition of recombinantly
20 produced gp120s and SOSIPs derived from neutralization resistant viruses. Combinatorial libraries with input
21 from x-ray crystallography, antibody lineage analysis, neutralization escape residues, and liability analysis will
22 also inform design. Emphasis will be placed on reduction of auto/polyreactive properties by aggressively
23 negatively selecting against those binding membrane proteins, immunogenic prediction algorithms, and
24 germline reversion. After 3 rounds of engineering, we will produce 48 mAbs as human IgG1 containing the “LS”
25 half-life extension and evaluate the bNAbs for in vitro neutralization. Thereafter, 8 bNAbs will be tested for
26 auto/polyreactivity, expression titer, biochemical behavior, and in vivo half-life. The top two bNAbs will be
27 tested in humanized mouse models for ability to protection against cell-free and cell-associated HIV challenge.
28 Impact: The development of a single, fully pan-neutralizing antibody with desirable PK and solubility properties
29 absent discernable polyreactivity would be a major advance in efforts to develop approaches for immune-
30 based treatment and prevention of HIV.
1背景/原理:一种越来越受关注的替代暴露前预防方式是基于
2前提是预防可以安全地实现被动免疫与广泛中和抗艾滋病毒
3种抗HIV包膜抗体(bNAb)。泛中和抗体可以提供一种可行的方法,
4.在全球范围内预防艾滋病毒感染。
5目的:我们的假设是,通过合理工程化接近泛中和的bNAb,
6结合位点(CD 4 bs)bNAbs N49 P7和N49P9.3,使用HIV的罕见抗性变体作为指导,
7中和,具有临床相关的药代动力学特征。这种泛中和抗体
8甚至将涵盖对其他抗CD 4 b bNAb(3BNC 117和N6)具有交叉抗性的变体。我们有
9初步数据表明N49 P7和N49P9.3接近泛中和,并表现出新的结构
10个特征(例如,N49 P7可进入高度保守的内部结构域),其可用于指导改进的
11 bNAb设计。这些独特的功能提供了最接近的起点,建立一个高效的泛-
12中和抗体。与此同时,我们的合作者已经开发了工程化bNAb的技术,
13的效力PGT 121约50倍,同时保留有利的品质(溶解性和非溶解性)。
14自体/多反应性)。本建议书的具体目标是:1)工程师N49 P7和N49P9.3,
2)来自Aim 1的bNAb变体的向下选择
3)在两个细胞中测试工程化的N49 bNAb;
17人源化小鼠模型使用耐药病毒,以确定其在预防HIV-1感染中的功效。
18方法:我们的计划是收集具有更大效力和广度的N49 P7和N49P9.3变体
19使用酵母表面展示,专注于选择具有增强的重组识别的变体。
20个产生了来自中和抗性病毒的gp 120和SOSIP。带输入的组合库
21从x射线晶体学,抗体谱系分析,中和逃逸残留物,和责任分析,
第22章也是设计重点将放在减少自动/多反应性能,
23针对那些结合膜蛋白的阴性选择,免疫原性预测算法,和
24个生殖系回复。经过3轮工程改造,我们将产生48株含有“LS”的人IgG 1单抗。
25半衰期延长,并评估bNAb的体外中和。此后,将检测8个bNAb,
26自身/多反应性、表达滴度、生物化学行为和体内半衰期。排名前两位的bNAb将是
在人源化小鼠模型中测试了27种抗无细胞和细胞相关HIV攻击的能力。
28影响:开发具有理想PK和溶解度特性的单一、完全泛中和抗体
缺乏可辨别的多反应性将是开发免疫治疗方法的一个重大进展。
30基于艾滋病毒的治疗和预防。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mohammad Mohseni Sajadi其他文献
Mohammad Mohseni Sajadi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mohammad Mohseni Sajadi', 18)}}的其他基金
COVID-19: Elucidating monoclonal and polyclonal seroantibody responses to the COVID-19 viral envelope
COVID-19:阐明对 COVID-19 病毒包膜的单克隆和多克隆血清抗体反应
- 批准号:
10513290 - 财政年份:2021
- 资助金额:
$ 40.1万 - 项目类别:
Engineering of pan-neutralizing anti-HIV envelope antibodies
全中和抗 HIV 包膜抗体的工程
- 批准号:
10304133 - 财政年份:2019
- 资助金额:
$ 40.1万 - 项目类别:
Engineering of pan-neutralizing anti-HIV envelope antibodies
全中和抗 HIV 包膜抗体的工程
- 批准号:
9927080 - 财政年份:2019
- 资助金额:
$ 40.1万 - 项目类别:
Engineering of pan-neutralizing anti-HIV envelope antibodies
全中和抗 HIV 包膜抗体的工程
- 批准号:
10064993 - 财政年份:2019
- 资助金额:
$ 40.1万 - 项目类别:
HIV-1 acidic epitope discovery from broadly neutralizing seroantibodies
从广泛中和血清抗体中发现 HIV-1 酸性表位
- 批准号:
9182870 - 财政年份:2014
- 资助金额:
$ 40.1万 - 项目类别:
Discovery of acidic epitopes for HIV-1 broadly neutralizing seroantibodies
发现 HIV-1 广泛中和血清抗体的酸性表位
- 批准号:
9788183 - 财政年份:2014
- 资助金额:
$ 40.1万 - 项目类别:
HIV-1 acidic epitope discovery from broadly neutralizing seroantibodies
从广泛中和血清抗体中发现 HIV-1 酸性表位
- 批准号:
8968228 - 财政年份:2014
- 资助金额:
$ 40.1万 - 项目类别:
相似海外基金
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 40.1万 - 项目类别:
Standard Grant
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 40.1万 - 项目类别:
Operating Grants
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 40.1万 - 项目类别:
Grant for R&D
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 40.1万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 40.1万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 40.1万 - 项目类别:
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 40.1万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 40.1万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 40.1万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 40.1万 - 项目类别:
Fellowship Programs